CRSP
SinkerCRISPR Therapeutics AG · Healthcare · Switzerland · $4.8B cap · $69.6M/day traded
$42.62 -6.8% · close 12 Nov · scored 13 Nov
Sinker: Weak business, rich price and weak momentum. Nothing here to keep it afloat.
As of 13 Nov 2026, the MoatMap Score for CRISPR Therapeutics AG (CRSP) is 11/100, ranked against 25,000+ stocks in 38 markets (Quality 23, Value 26, Momentum 36, each scored against its sector).
Does the score work? Each tenth of the ranking, tracked monthly. See the record →
ABOUT CRISPR THERAPEUTICS AG
Read
CRISPR Therapeutics AG is a leading gene editing company leveraging its proprietary CRISPR/Cas9 technology to develop transformative gene-based medicines for serious genetic diseases and cancers. As a pioneer in the field, it holds foundational intellectual property and has brought the first CRISPR-based gene therapy, Casgevy, to market, establishing a significant early competitive advantage.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.4M | 370.0M | 35.0M | 0 | 796.0% | 25.2M | 35.4M | 133.4M | 56.2% |
| EPS | -8.36 | -1.94 | -4.34 | -6.47 | — | -4.73 | -4.54 | -3.69 | — |
| Shares | 78.5M | 80.0M | 85.7M | 95.9M | +22.1% | 97.0M | — | — | — |
| Debt | 244.0M | 238.6M | 223.7M | 206.7M | -5.4% | 779.8M | — | — | — |
| Equity | 1.9B | 1.9B | 1.9B | 1.9B | 0.8% | — | — | — | — |
| Op CF | -495.7M | -260.4M | -142.8M | -345.0M | — | -374.6M | — | — | — |
| Inv CF | -258.7M | 374.6M | -280.5M | -31.8M | — | — | — | — | — |
| Fin CF | 38.6M | 62.7M | 332.0M | 426.0M | — | — | — | — | — |
No clear trend: not near its 52-week low, and not in a steady uptrend.
Swung more than 73% of stocks we rank over the past year (volatility 58% a year).
How this is worked out
The Price check reads only the chart, the price side of the Momentum score in words; it is not the MoatMap Score.
- Still falling: It set a new 52-week low in the last two weeks, after a deep fall.
- Finding a floor: It fell hard, but has set no new low for more than two weeks.
- Turning up: It has climbed off its low and is back above a rising 50-day average.
- In an uptrend: It is near its 52-week high and above its 200-day average.
- No clear trend (this stock): None of the above: no recent deep fall and no steady climb.
- No read yet: Not enough price history yet: it needs a year of trading.
In past US falls, waiting for Turning up cut the chance of another 20% drop from 42% to 33%. Returns were no better, and 33% of turns failed.
The exact rules
Still falling is a new 52-week low in the last two weeks, at least 25% below the high, with the low set after the high. Finding a floor is the same fall with no new low in the last two weeks. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average, with the 50-day average above the 200-day, and within 15% of the high. No clear trend is everything else. No read yet is under 252 trading days of history, or missing data. A new state shows once it has held for three trading days.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn (the Turning up rule above) cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: how much the price moved day to day over the past year, scaled to a yearly figure (annualised volatility) and ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CRSP are excluded.
| Ticker | Company | Mkt Cap | Score |
|---|---|---|---|
| CRSP | CRISPR Therapeutics AG(you) | $4.8B | 11 |
| PHVS | Pharvaris N.V. | $2.2B | 19 |
| IDIA.SW | Idorsia Ltd | $1.4B | 15 |
| MLTX | MoonLake Immunotherapeutics | $1.0B | 8 |
| OCS | Oculis Holding AG | $487M | 8 |
| BANB.SW | Bachem Holding AG | $7.5B | 50 |
| ACIU | AC Immune SA | $299M | 12 |
| BIOV.SW | BioVersys AG | $175M | 13 |
| SANN.SW | Santhera Pharmaceuticals Holding AG | $257M | 25 |
| MOLN | Molecular Partners AG | $165M | 17 |
Peer medians: ROE 10.7% · P/E 37.4x · Gross margin 59.2%
Company Deep Dive
A 10,000-word report: the business and its segments, what management promised on earnings calls and whether it delivered, the competition, and how things could turn out.